FY2029 Earnings Estimate for PRCT Issued By Leerink Partnrs

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for shares of PROCEPT BioRobotics in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky forecasts that the company will earn $0.48 per share for the year. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share.

A number of other equities research analysts also recently weighed in on PRCT. Wells Fargo & Company reaffirmed an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley lowered their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday. Truist Financial reissued a “buy” rating and set a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Finally, Jefferies Financial Group initiated coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a “hold” rating and a $95.00 target price for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.29.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT opened at $64.34 on Thursday. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics has a fifty-two week low of $45.56 and a fifty-two week high of $103.81. The firm has a 50-day simple moving average of $74.93 and a 200 day simple moving average of $79.84. The company has a market cap of $3.36 billion, a PE ratio of -32.99 and a beta of 1.03.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million for the quarter, compared to the consensus estimate of $66.79 million.

Institutional Trading of PROCEPT BioRobotics

A number of institutional investors have recently made changes to their positions in PRCT. Creative Planning lifted its stake in shares of PROCEPT BioRobotics by 88.9% in the 3rd quarter. Creative Planning now owns 9,948 shares of the company’s stock worth $797,000 after acquiring an additional 4,681 shares during the period. International Assets Investment Management LLC lifted its stake in PROCEPT BioRobotics by 12,919.5% during the third quarter. International Assets Investment Management LLC now owns 52,078 shares of the company’s stock valued at $4,172,000 after purchasing an additional 51,678 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in PROCEPT BioRobotics by 178.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock valued at $89,000 after purchasing an additional 713 shares during the last quarter. Oak Ridge Investments LLC acquired a new stake in PROCEPT BioRobotics during the third quarter valued at approximately $1,942,000. Finally, Americana Partners LLC acquired a new stake in PROCEPT BioRobotics during the third quarter valued at approximately $1,494,000. 89.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 26,423 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the sale, the chief executive officer now directly owns 152,762 shares of the company’s stock, valued at approximately $14,851,521.64. This represents a 14.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Alaleh Nouri sold 28,092 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the sale, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).